Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:56:12.219Z.
Consensus retrieved: 2026-10-06T11:08:12.049Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:56:12.219Z.
Quote observation: 2026-10-06T15:54:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26b9d76e1867df839f3ea79fd47ae1c5236575fa33f8c6240ddbf9d3395e1dfe
Forward PE Ratio (N/A) = Dated Quote Price ($1.90) / Consensus Forward EPS ($-1.88)
FORWARD PE RATIO
N/A
Elicio Therapeutics, Inc.
Market Cap
$36.23M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $36.23M | N/A |
| DocGo Inc. (DCGO)vs › | $35.91M | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.63M | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.67M | N/A |
| Elutia Inc (ELUT)vs › | $35.28M | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.28M | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.58M | N/A |
| Accuray Incorporated (ARAY)vs › | $34.54M | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.93M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.90, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.88 | $-2.15 – $-1.68 | 3 | n/m |
| 2027-12-31 | $-1.69 | $-2.25 – $-1.13 | 3 | n/m |
| 2028-12-31 | $-1.18 | $-1.18 – $-1.18 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
